title: Oxidative metabolism of the carcinogen 6-fluorobenzo[c]phenanthrene. Effect of a K-region fluoro substituent on the regioselectivity of cytochromes P-450 in liver microsomes from control and induced rats.
abstract: Oxidative metabolism of the carcinogen 6-fluorobenzo[c]phenanthrene (6-FB[c]Ph) was compared with that of benzo[c]phenanthrene (B[c]Ph) to elucidate the enhancement of carcinogenicity of B[c]Ph by the 6-fluoro substituent. Liver microsomes from untreated (control), phenobarbital-treated, and 3-methylcholanthrene-treated rats metabolized 6-FB[c]Ph at rates of 3.5, 1.5, and 7.7 nmol of products/nmol of cytochrome P-450/min, respectively. The rates of metabolism of B[c]Ph by the same microsomes were 2.9, 1.6, and 5.5 nmol of products/nmol of cytochrome P-450/min, respectively. Whereas the K-region 5,6-dihydrodiol was the major metabolite of B[c]Ph, the major metabolite of 6-FB[c]Ph was the K-region 7,8-oxide, which underwent slow rearrangement to an oxepin. Thus, the 6-fluoro substituent blocks oxidation at the 5,6-double bond and inhibits hydration of the K-region 7,8-oxide by epoxide hydrolase. Substitution with fluorine at C-6 caused an almost 2.5-fold increase in the percentages of the putative proximate carcinogens, i.e. benzo-ring dihydrodiols with bay-region double bonds, when liver microsomes from 3-methylcholanthrene-treated rats were used. Little or no increase was observed in their formation by liver microsomes from control or phenobarbital-treated rats. Interestingly, liver microsomes from control rats formed almost 3-fold as much 3,4-dihydrodiol as isosteric 9,10-dihydrodiol. The R,R-enantiomers of the 3,4- and 9,10-dihydrodiols and the S,S-enantiomer of the 7,8-dihydrodiol were predominantly formed by all three microsomal preparations.
authors.affiliation: Laboratory of Molecular Pharmacology, Food and Drug Administration, Bethesda, Maryland 20892.
authors.forename: G K
authors.initials: GK
authors.lastname: Prasad
authors.forename: S
authors.initials: S
authors.lastname: Mirsadeghi
authors.forename: C
authors.initials: C
authors.lastname: Boehlert
authors.forename: R A
authors.initials: RA
authors.lastname: Byrd
authors.forename: D R
authors.initials: DR
authors.lastname: Thakker
mesh_terms: D000818:Animals; D001665:Binding Sites; D002273:Carcinogens / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D006845:Hydrocarbons, Fluorinated / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008748:Methylcholanthrene / Q000494:pharmacology; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism*; D008968:Molecular Conformation; D010084:Oxidation-Reduction; D010616:Phenanthrenes / Q000378:metabolism*; D010634:Phenobarbital / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D012016:Reference Values; D013329:Structure-Activity Relationship
chemical_list: D002273:Carcinogens; D006845:Hydrocarbons, Fluorinated; D010616:Phenanthrenes; C055179:6-fluorobenzo(c)phenanthrene; D008748:Methylcholanthrene; D003577:Cytochrome P-450 Enzyme System; C002615:benzo(c)phenanthrene; D010634:Phenobarbital